Nasdaq

Biogen Announces FDA Approval of PLEGRIDY® (peginterferon beta-1a) Intramuscular Administration for Multiple Sclerosis

Intramuscular injection PLEGRIDY (peginterferon beta-1a) is now approved in the U.S. and the European Union, offering individuals with relapsing multiple sclerosis (MS) a treatment option with ...
The American Journal of Managed Care

FDA Issues CRL for Glatiramer Acetate Depot for Relapsing Forms of MS

The FDA has declined to approve glatiramer acetate (GA) depot in the treatment of relapsing types of multiple sclerosis (MS), issuing a complete response letter (CRL) for the long-acting, injectable ...
Nature

Intramuscular Injection Techniques and Sciatic Nerve Injury

Intramuscular injection remains a cornerstone of clinical practice, offering rapid drug absorption and efficacy when performed correctly. However, its success is intrinsically linked to precise ...
Monthly Prescribing Reference

Insulin Pump vs. Multiple Injections in Poorly Controlled T2D

(HealthDay News) — For patients with poorly controlled type 2 diabetes, pump treatment is associated with improved glycemic control vs. multiple daily injections, according to a study published online ...
Nasdaq

Biogen Announces FDA Approval of PLEGRIDY® (peginterferon beta-1a) Intramuscular Administration for Multiple Sclerosis

CAMBRIDGE, Mass., Feb. 01, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that the U.S. Food and Drug Administration (FDA) has approved a new intramuscular (IM) injection route of ...